ArticleBlood cancer journal2024

Comparing venetoclax in combination with hypomethylating agents to hypomethylating agent-based therapies for treatment naive TP53-mutated acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND).

Talha Badar et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.